Compare CHMI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | INKT |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 51.7M |
| IPO Year | 2013 | 2021 |
| Metric | CHMI | INKT |
|---|---|---|
| Price | $2.49 | $11.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.75 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 290.8K | 19.5K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | ★ 16.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $40,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.73 | N/A |
| P/E Ratio | $132.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $4.56 |
| 52 Week High | $3.68 | $76.00 |
| Indicator | CHMI | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 44.93 |
| Support Level | $2.20 | $10.51 |
| Resistance Level | $2.52 | $12.50 |
| Average True Range (ATR) | 0.09 | 0.87 |
| MACD | 0.03 | 0.12 |
| Stochastic Oscillator | 88.57 | 41.42 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.